Opiant Pharmaceuticals Inc(OPNT)stock report

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Finance:
2019第三季度扭亏为盈

EPS and Sales:
https://finance.yahoo.com/quote/OPNT/financials?p=OPNT

Date EPS % last year % last quarter
2018.12.31 -7.1 / -39.15%
2019.3.31 -0.44 88.04% 93.80%
2019.6.30 -0.04 99.03% 90.91%
2019.9.30 2.64 161.11% 6700.00%

 

Date Sales % last year % last quarter
2018.12.31 13.98M / 34.05%
2019.3.31 5.44M 219.14% -61.09%
2019.6.30 12.21M 151.60% 124.45%
2019.9.30 32.85M 256.30% 169.04%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=OPNT&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/OPNT/institutional-ownership/

2019.11.13更新:
总机构数23家,较上期无变化
总持股数79.36万股,较上期无变化
持股比例19.64%,较上期无变化

Analyst Ratings:
https://www.tipranks.com/stocks/OPNT/price-targe

Leave a Reply